Zimmer Biomet has reported Q2 revenues of around $2.18bn, denoting a year-over-year (YoY) uptick of 4.8%, and a revised full year outlook.
Zimmer’s knees segment was its strongest performer in Q2, with sales totalling $828.9m, followed by S.E.T. (Sports Medicine, Extremities, Trauma, Craniomaxillofacial and Thoracic) at $586m, and hips at $562.7m
However, while Zimmer’s technology and data, bone cement and surgical segment drew in the lowest profits in Q2 at $199.4m, this segment saw the largest YoY growth at 21.1%, followed by S.E.T. at 6.4% and hips at 5%. Meanwhile, YoY growth in knees remained flat at 0.4%. The orthopaedics giant now expects 2026 revenue growth to land in the 3.9% to 4.9% range, up from 2.5% to 4.5% previously, with earnings now mooted to come in at $8.47-$8.59 per diluted share, up from $8.40-$8.55 previously.
Zimmer released its Q2 financials ahead of market open. The company’s shares on the New York Stock Exchange (NYSE) rose by over 5% to around $101.00 at market open on 5 August, up from $95.81 previously. Zimmer Biomet has a market cap of $19.63bn.